27 research outputs found
The Monarch Initiative in 2019: an integrative data and analytic platform connecting phenotypes to genotypes across species.
In biology and biomedicine, relating phenotypic outcomes with genetic variation and environmental factors remains a challenge: patient phenotypes may not match known diseases, candidate variants may be in genes that haven\u27t been characterized, research organisms may not recapitulate human or veterinary diseases, environmental factors affecting disease outcomes are unknown or undocumented, and many resources must be queried to find potentially significant phenotypic associations. The Monarch Initiative (https://monarchinitiative.org) integrates information on genes, variants, genotypes, phenotypes and diseases in a variety of species, and allows powerful ontology-based search. We develop many widely adopted ontologies that together enable sophisticated computational analysis, mechanistic discovery and diagnostics of Mendelian diseases. Our algorithms and tools are widely used to identify animal models of human disease through phenotypic similarity, for differential diagnostics and to facilitate translational research. Launched in 2015, Monarch has grown with regards to data (new organisms, more sources, better modeling); new API and standards; ontologies (new Mondo unified disease ontology, improvements to ontologies such as HPO and uPheno); user interface (a redesigned website); and community development. Monarch data, algorithms and tools are being used and extended by resources such as GA4GH and NCATS Translator, among others, to aid mechanistic discovery and diagnostics
Ready-to-use therapeutic food with elevated n-3 polyunsaturated fatty acid content, with or without fish oil, to treat severe acute malnutrition: a randomized controlled trial
Shear Wave Splitting and Mantle Anisotropy: Measurements, Interpretations, and New Directions
A Preliminary Evaluation of Virginia Fresh Match: Impacts and Demographic Considerations for Future Fruit and Vegetable Incentive Programs
The purpose of this communication is to describe the preliminary evaluation of the Virginia Fresh Match (VFM) financial incentive program for fresh fruits and vegetables for Virginia Supplemental Nutrition Assistance Program shoppers and to determine if there were differences in incentive outcomes by race. In this cross-sectional study, a questionnaire was administered to shoppers using Virginia Fresh Match incentives at participating farmers markets and community-based food retail outlets. Repeated measures ANOVAs were used to detect differences in fruit and vegetable consumption between demographic groups over time. Chi-square tests were used to determine if there were associations between race and perceived impact of VFM incentives on making food last and the attribution of VFM incentives to changes in fruit and vegetable consumption frequency. Frequency of fruit and vegetable intake was significantly higher during VFM incentive use, with a difference of 1.17 ± 0.07 and 1.07 ± 0.07 on a Likert scale measure, respectively (p ≤ 0.001). There were racial differences in assertions that VFM incentives helped food to last. VFM incentives were effective at increasing fruit and vegetable consumption, but racial differences should be considered in the administration of VFM to avoid reinforcing systems or approaches that may contribute to disparities in food access and food security
Perceptions of barriers and facilitators: Self-management decisions by older adolescents and adults with CF
High-Throughput Luciferase-Based Assay for the Discovery of Therapeutics That Prevent Malaria
In order to identify the most attractive
starting points for drugs that can be used to prevent malaria, a diverse
chemical space comprising tens of thousands to millions of small molecules
may need to be examined. Achieving this throughput necessitates the
development of efficient ultra-high-throughput screening methods.
Here, we report the development and evaluation of a luciferase-based
phenotypic screen of malaria exoerythrocytic-stage parasites optimized
for a 1536-well format. This assay uses the exoerythrocytic stage
of the rodent malaria parasite, Plasmodium berghei, and a human hepatoma cell line. We use this assay to evaluate several
biased and unbiased compound libraries, including two small sets of
molecules (400 and 89 compounds, respectively) with known activity
against malaria erythrocytic-stage parasites and a set of 9886 diversity-oriented
synthesis (DOS)-derived compounds. Of the compounds screened, we obtain
hit rates of 12–13 and 0.6% in preselected and naïve
libraries, respectively, and identify 52 compounds with exoerythrocytic-stage
activity less than 1 μM and having minimal host cell toxicity.
Our data demonstrate the ability of this method to identify compounds
known to have causal prophylactic activity in both human and animal
models of malaria, as well as novel compounds, including some exclusively
active against parasite exoerythrocytic stages
High-Throughput Luciferase-Based Assay for the Discovery of Therapeutics That Prevent Malaria
In order to identify the most attractive
starting points for drugs that can be used to prevent malaria, a diverse
chemical space comprising tens of thousands to millions of small molecules
may need to be examined. Achieving this throughput necessitates the
development of efficient ultra-high-throughput screening methods.
Here, we report the development and evaluation of a luciferase-based
phenotypic screen of malaria exoerythrocytic-stage parasites optimized
for a 1536-well format. This assay uses the exoerythrocytic stage
of the rodent malaria parasite, Plasmodium berghei, and a human hepatoma cell line. We use this assay to evaluate several
biased and unbiased compound libraries, including two small sets of
molecules (400 and 89 compounds, respectively) with known activity
against malaria erythrocytic-stage parasites and a set of 9886 diversity-oriented
synthesis (DOS)-derived compounds. Of the compounds screened, we obtain
hit rates of 12–13 and 0.6% in preselected and naïve
libraries, respectively, and identify 52 compounds with exoerythrocytic-stage
activity less than 1 μM and having minimal host cell toxicity.
Our data demonstrate the ability of this method to identify compounds
known to have causal prophylactic activity in both human and animal
models of malaria, as well as novel compounds, including some exclusively
active against parasite exoerythrocytic stages
Serum protein profiles predict coronary artery disease in symptomatic patients referred for coronary angiography
Background: More than a million diagnostic cardiac catheterizations are performed annually in the US for evaluation of coronary artery anatomy and the presence of atherosclerosis. Nearly half of these patients have no significant coronary lesions or do not require mechanical or surgical revascularization. Consequently, the ability to rule out clinically significant coronary artery disease (CAD) using low cost, low risk tests of serum biomarkers in even a small percentage of patients with normal coronary arteries could be highly beneficial. Methods: Serum from 359 symptomatic subjects referred for catheterization was interrogated for proteins involved in atherogenesis, atherosclerosis, and plaque vulnerability. Coronary angiography classified 150 patients without flow-limiting CAD who did not require percutaneous intervention (PCI) while 209 required coronary revascularization (stents, angioplasty, or coronary artery bypass graft surgery). Continuous variables were compared across the two patient groups for each analyte including calculation of false discovery rate (FDR ≤ 1%) and Q value (P value for statistical significance adjusted to ≤ 0.01). Results: Significant differences were detected in circulating proteins from patients requiring revascularization including increased apolipoprotein B100 (APO-B100), C-reactive protein (CRP), fibrinogen, vascular cell adhesion molecule 1 (VCAM-1), myeloperoxidase (MPO), resistin, osteopontin, interleukin (IL)-1β, IL-6, IL-10 and N-terminal fragment protein precursor brain natriuretic peptide (NT-pBNP) and decreased apolipoprotein A1 (APO-A1). Biomarker classification signatures comprising up to 5 analytes were identified using a tunable scoring function trained against 239 samples and validated with 120 additional samples. A total of 14 overlapping signatures classified patients without significant coronary disease (38% to 59% specificity) while maintaining 95% sensitivity for patients requiring revascularization. Osteopontin (14 times) and resistin (10 times) were most frequently represented among these diagnostic signatures. The most efficacious protein signature in validation studies comprised osteopontin (OPN), resistin, matrix metalloproteinase 7 (MMP7) and interferon γ (IFNγ) as a four-marker panel while the addition of either CRP or adiponectin (ACRP-30) yielded comparable results in five protein signatures. Conclusions: Proteins in the serum of CAD patients predominantly reflected (1) a positive acute phase, inflammatory response and (2) alterations in lipid metabolism, transport, peroxidation and accumulation. There were surprisingly few indicators of growth factor activation or extracellular matrix remodeling in the serum of CAD patients except for elevated OPN. These data suggest that many symptomatic patients without significant CAD could be identified by a targeted multiplex serum protein test without cardiac catheterization thereby eliminating exposure to ionizing radiation and decreasing the economic burden of angiographic testing for these patients.National Institutes of Health (U.S.) (NIH/NCI Cancer Center Support Grant (WALaF: co-investigator: 3P30 CA047904-20S1)